Efficacy of combined Sofosbuvir and Daclatasvir in the treatment of COVID-19 patients with pneumonia: a multicenter Egyptian study.

Mahmoud El-BendarySherief Abd-ElsalamTamer ElbazWafaa El-AkelAhmed CordieTamer ElhadidyHatem ElalfyKhaled FaridMohamed ElegezyAdel El-BadrawyMustafa NeamatallahMohamed Abd ElghafarMarwa SalamaMohamed AbdAllahMahmoud EssamMostafa El-ShazlyGamal Esmat

Published in: Expert review of anti-infective therapy (2021)

Adding sofosbuvir/daclatasvir to conventional therapy of COVID-19 is promising. Their use is associated with shorter hospital stay, faster PCR negativity and may be reduced mortality.

Keyphrases

hepatitis c virus
coronavirus disease
sars cov
hepatitis c virus infection
combination therapy
respiratory syndrome coronavirus
cross sectional
emergency department
cardiovascular disease
stem cells
intensive care unit
replacement therapy
cell therapy